Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.

JCO precision oncology - 1 Feb 2022

Yap Timothy A, Hamilton Erika, Bauer Todd, Dumbrava Ecaterina E, Jeselsohn Rinath, Enke Aaron, Hurley Sabrina, Lin Kevin K, Habeck Jenn, Giordano Heidi, Shapiro Geoffrey I

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin
Share to Immunoconjugates

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Indoles

Share to Mutation

Share to Neoplasms

Share to Recombinational DNA Repair

Source

Open in PubMed Open full text

Identifiers

PMID: 35138920
DOI: 10.1200/PO.21.00456
PMCID: PMC8865521

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.PMID 35138920Read ↗

WITHDRAWN: Rucaparib in patients presenting a metastatic breast cancer with Homologous Recombination Deficiency, without germline BRCA1/2 mutationSemantic proximity Read ↗

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400GSemantic proximity Read ↗

Ovarian cancer: Status of homologous recombination pathway as a predictor of drug responseSemantic proximity Read ↗

263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)Semantic proximity Read ↗

A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparibSemantic proximity Read ↗

Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.Semantic proximity Read ↗

Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51Semantic proximity Read ↗

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)Semantic proximity Read ↗

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancerSemantic proximity Read ↗

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.Semantic proximity Read ↗

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.